Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer

This is an open label, multicenter, single arm phase II study to evaluate the efficacy and safety of ribociclib and ET in patients with locoregional recurrence of HR-positive, HER2-negative breast cancer.

Trial Details

NCT ID

NCT05467891

Phase

PHASE2

Sponsor

Oana Danciu

Status

RECRUITING

Cancer Type

ER/PR Positive (Hormone Receptor Positive) Breast Cancer

Interventions

Ribociclib
Fulvestrant
Anastrozole
Letrozole
Exemestane

Locations (sample)

Birmingham, Alabama, United States|33.52066,-86.80249
Phoenix, Arizona, United States|33.44838,-112.07404
Orlando, Florida, United States|28.53834,-81.37924
Chicago, Illinois, United States|41.85003,-87.65005
Fort Wayne, Indiana, United States|41.1306,-85.12886

Key Eligibility Criteria

Subject must meet all of the following applicable inclusion criteria to participate in this study:
Written informed consent (stage II/ main consent) and HIPAA authorization for release of personal health information obtained prior to performing a…
Male or female age ≥ 18 years at the time of consent. NOTE: Both pre- and post-menopausal women are eligible. Post-menopausal status is defined as:
Prior bilateral oophorectomy

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find ER/PR Positive (Hormone Receptor Positive) Breast Cancer Trials on Trialify →